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Purpose: Conditions and thresholds applied for evidence weighting of within-codon
concordance (PM5) for pathogenicity vary widely between laboratories and expert groups.
Because of the sparseness of available clinical classifications, there is little evidence for
variation in practice.
Methods: We used as a truthset 7541 dichotomous functional classifications of BRCA1 and
MSH2, spanning 311 codons of BRCA1 and 918 codons of MSH2, generated from large-scale
functional assays that have been shown to correlate excellently with clinical classifications.
We assessed PM5 at 5 stringencies with incorporation of 8 in silico tools. For each analysis,
we quantified a positive likelihood ratio (pLR, true positive rate/false positive rate), the
predictive value of PM5-lookup in ClinVar compared with the functional truthset.
Results: pLR was 16.3 (10.6-24.9) for variants for which there was exactly 1 additional colo-
cated deleterious variant on ClinVar, and the variant under examination was equally or more
damaging when analyzed using BLOSUM62. pLR was 71.5 (37.8-135.3) for variants for which
there were 2 or more colocated deleterious ClinVar variants, and the variant under examination
was equally or more damaging than at least 1 colocated variant when analyzed using
BLOSUM62.
Conclusion: These analyses support the graded use of PM5, with potential to use it at higher
evidence weighting where more stringent criteria are met.
© 2021 The Authors. Published by Elsevier Inc. on behalf of American College of Medical
Genetics and Genomics. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Variant interpretation
Sequence analysis of constitutional DNA has informed
diagnosis and prediction of human Mendelian diseases for
>3 decades. Correct identification of the causative patho-
genic variant is necessary if prediction of the clinical course
of disease, implementation of measures for prevention, andqually.
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2 L. Loong et al.Pathology (ACMG/AMP).2 This framework comprises 5
levels of variant classification based on weighted summing
of different lines of evidence such as clinical case series,
segregation data, phenotypic specificity, and laboratory
(functional) assays.2 In parallel, ClinVar has been estab-
lished as a freely available public repository for classifica-
tions, hosted by the National Center for Biotechnology
Information.3 Its ranking system reflects the robustness of
the classification; a 3-star classification is only awarded if
the classification has been awarded by (1) a ClinVar
recognized expert panel or (2) a ClinGen Variant Curation
Expert Panel (VCEP), an expert panel providing Food and
Drug Administration–recognized variant interpretation us-
ing ACMG/AMP evidence codes and specifications.4
Within-codon concordance of pathogenic variants
(PM5)
In many regions of a gene, variants are well tolerated without
discernible effect on protein function. However, there are
residues at which substitution of even a seemingly similar
amino acid will have a dramatic effect on the structure and/or
function of the protein. It is thus reasonable to hypothesize
that a codon at which other previously-encountered missense
substitutions have been shown to be pathogenic encodes an
amino acid that is structurally and/or functionally important.
Hence, a novel missense substitution identified at that codon
is relatively more likely than average to also be pathogenic.
Conversely, it is reasonable to hypothesize that at a codon at
which previously-encountered missense substitutions have all
been shown to be benign, the amino acid is overall likely to
be nonessential to protein structure and function. A novel
missense substitution at that codon is thus overall more likely
than average to be benign. This is a well-cemented axiom in
interpretation of novel sequence variants, and is ascribed
moderate evidence (evidence item PM5) in the 2015 ACMG/
AMP variant interpretation framework.2 However, specifi-
cations by different VCEPs of rules around the usage of PM5
vary widely, eg, prescribing different evidence weighting,
incorporating different in silico tools, allowing application
across paralogous genes, or prohibiting the use of PM5
altogether.5-9. For most genes, clinical variant classifications
are typically only available for a very sparse set of variants
that are potentially biased toward particular regions and co-
dons. This means that the validation and therefore justifica-
tion of the different VCEP PM5 specifications to date have
been limited.10 PM5 is widely used across laboratories for
variant interpretation. Correct calibration of evidence
weighting and combination is essential to ensure that our
final classifications of variants are accurate.
In silico predictions of effect of missense variants
Amino acids vary in composition, polarity, and
molecular volume. More dramatic differences betweenwild-type and variant amino acids in these physioche-
mical parameters are more likely to alter the structure
and thus function of the protein. In 1974, Grantham11
proposed the Grantham Difference as a score for quanti-
fying this physiochemical difference between amino
acids. Following this, amino acid substitution scoring
matrices such as the PAM250 or BLOSUM scores
incorporated pairwise comparisons of physiochemical
characteristics alongside evolutionary substitution fre-
quencies.12 In subsequent tools, such as Align-GVGD,
protein multiple sequence alignments were also incorpo-
rated to capture the essentiality of the wild-type amino
acid as well as the physiochemical magnitude of the
substitution.13 Numerous subsequent in silico tools have
emerged, which variously predict the severity of the effect
of a missense variant using these and other elements, such
as predicted disruption to 3-dimensional protein struct-
ure, information about protein domains, clinical annota-
tions, and population allele frequency data. Newer
meta tools such as REVEL and Meta-SNP use machine
learning across multiple tools to optimize predictive
performance.14
Large-scale functional assays of cancer
susceptibility genes
The deleteriousness of a missense variant can also be
quantified by measuring, in an ex vivo cellular construct, its
effect on a relevant cellular function. Early functional assays
were laborious and thus low throughput; typically only a
selected handful of clinically-observed variants would be
included. After the advances in gene editing technology and
multiplex assay design, high throughput saturation genome
editing experiments have made it possible to assay simul-
taneously many thousands of variants via robust systematic
methodologies called multiplex assays of variant effect
(MAVEs).15 For some MAVEs for which sufficient clinical
classifications exist for comparison, high concordance has
been shown with discrepancies highlighting potential clin-
ical misclassifications.16
MAVEs provide unbiased systematic functional classi-
fications of (nearly) every missense variant that can arise
by single base substitution at a codon. These data sets
therefore offer a novel opportunity for evaluation of PM5.
To explore this further, we selected 2 MAVEs (for BRCA1
and MSH2) for which (1) adequate validation had been
possible because multiple ClinVar Expert Panel 3-star
clinical classifications of benign and pathogenic variants
are available on ClinVar, (2) the MAVE has not yet been
widely used by the Expert Panels for generation of these
clinical classifications, and (3) high concordance of
MAVE-functional classifications with clinical classifica-
tions has been shown. In this study, we explored for these 2
genes the predictive strength of PM5, quantified as a
likelihood ratio.
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Functional classifications for BRCA1 and MSH2
variants
For BRCA1, we used data on 3893 single-nucleotide vari-
ants in the 13 exons encompassing the RING finger motif
and BRCT (BRCA1 C-terminal) functional domain, gener-
ated by Findlay et al16 using saturation mutagenesis. Findlay
et al16 assessed variant-BRCA1 function using an assay of
cellular fitness of HAP1 cells (a near-haploid cancer cell
line). For MSH2, we used data on 5212 MSH2 amino acid
substitutions that corresponded to 5734 nonsynonymous
single-nucleotide variants, generated by Jia et al17 using
saturation mutagenesis. Jia et al17 assessed variant-MSH2
function using an assay of HAP1 cellular survival after
treatment with 6-thioguanine, which is selectively toxic to
mismatch repair proficient cells as it induces lesions unre-
pairable by the mismatch repair machinery (Supplemental
Table 1). Data from RNA sequencing was only available
for BRCA1, and thus, for parity this was not included in the
main analysis. Each functional truthset was curated to
include only missense variants. Synonymous, nonsense, and
initiation codon variants were excluded. The potentially
spliceogenic exonic variants at the 2 bases flanking the
intron–exon boundary were also excluded (hereafter called
para-splice-site variants). Variants were described in
accordance with Human Genome Variation Society
nomenclature for GRCh37 transcripts ENST00000357654
(BRCA1) and ENST00000233146 (MSH2). The calculation
of PM5 positive likelihood ratios (pLRs) requires dichoto-
mous functional classifications, and therefore, variants with
intermediate assay activity were excluded. The remainder
were included as classified in their original publications as
either deleterious (DEL) or tolerated (TOL).
Clinical classifications for BRCA1 and MSH2 variants
We assembled available ClinVar classifications for missense
variants in the corresponding codons of BRCA1/MSH2,
again excluding para-splice-site variants. Variants with a
ClinVar classification of ≥1-star rating of pathogenic/likely
pathogenic (P/LP) or benign/likely benign (B/LB), were
assigned to dichotomous clinical classification groups:
ClinVar DEL or ClinVar TOL. The clinical classification
was designated as missing for variants for which there was
no classification, a classification of uncertain significance, or
conflicting interpretations of pathogenicity. The concor-
dance between clinical and functional classifications is
shown in Supplemental Table 2.
In silico annotations for BRCA1 and MSH2 variants
For each variant we retrieved predictions for selected in
silico tools. BLOSUM45, BLOSUM62, BLOSUM80,
Grantham Score, and Align-GVGD were selected becausethey specifically reflect the physiochemical difference be-
tween the wild-type and variant amino acid.11-13,18,19
REVEL, Meta-SNP, and CADD were selected because
these tools are widely-used clinically and/or assessed as
high-performing.14,20-22 In silico scores were retrieved using
Annovar (dbnsfp33a database), Alamut-HT, the Meta-SNP,
and REVEL webservers.14,20,23,24
Generation and evaluation of PM5 predictions
We considered 5 definitions of PM5 (PM5-definitions a-e)
of varying stringency relating to (1) number of DEL variants
colocated at the codon of interest (excluding the variant
under examination) and (2) whether the variant under ex-
amination had an equally or more damaging in silico pre-
diction than the colocated DEL variants, reflecting the
variation in existing VCEP criteria (Figure 1). PM5-
definition_a is the least stringent, whereas PM5-
definition_e is the most stringent, mandating the greatest
number of colocated DEL variants and requirement for more
damaging performance on in silico tools. Our primary
approach was PM5-lookup using clinical classifications
(classifications from ClinVar, n = 199) to make the PM5
prediction, referenced against a truthset of dichotomous
functional classifications (BRCA1/MSH2 MAVEs, n =
7541). All variants for which a dichotomous functional
classification was available were assessed; missense variants
were not included in the analysis if there was no MAVE
data or the MAVE output was intermediate.
If lookup for the variant under examination in ClinVar
met the stated conditions of the PM5 definition, the PM5
prediction was DEL. If the variant under examination did
not meet the stated conditions, the PM5 prediction was
TOL. The PM5 prediction was then compared with the
variant’s classification in the MAVE reference truthset.
Assignment of true positive (TP) was made for a variant for
which PM5 prediction in ClinVar was DEL and classifica-
tion in the MAVE reference truthset was also DEL, and
assignment of true negative (TN) was made when PM5
prediction in ClinVar was TOL and classification was TOL
in the MAVE reference truthset. The variant was assigned
false positive (FP) when the ClinVar PM5 prediction was
DEL but the classification in the MAVE reference truthset
was TOL. The variant was assigned false negative (FN)
when the ClinVar PM5 prediction was TOL but the classi-
fication in the in the MAVE reference truthset was DEL
(Figure 1, Supplemental Table 3).
We repeated these analyses first using the MAVE-
functional classifications for both the PM5-lookup and
reference truthset (Additional_Approach_1) and second
using ClinVar clinical classifications for both the PM5-
lookup and reference truthset (Additional_Approach_2)
(Figure 1).
For each analysis, we quantified PM5 pLRs, ie, the TP
rate/FP rate ([TP/(TP+FN)]/[FP/(TN+FP)]) (Table 1,
Supplemental Tables 4 and 5). We applied a Haldane-
Anscombe correction (0.5 added to each cell) to (1) allow
Figure 1 Schematic of PM5 analyses comparing prediction (lookup of colocated variants in the lookup data set) with a reference
truthset. Combinations of lookup data set and reference truthset for each analysis approach (top). Assignation of true positive, true negative,
false positive, and false negative (middle). Binary PM5 definitions of increasing stringency (a-e) and nonoverlapping banded PM5 definitions
(x, y) (bottom). DEL, deleterious; MAVE, multiplex assay of variant effect; TOL, tolerated.
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(2) to add a conservative correction. PM5 negative likeli-
hood ratios were also calculated ([TN/(TN+FP)]/[FN/
(FN+TP)]) (Supplemental Table 6).
In these binary analyses, variants that meet a more
stringent PM5-definition were included in the analyses of
less stringent definitions (eg, variants attaining PM5-
definition_e necessarily also attain PM5-definition_d). To
advance beyond this, we performed a banded analysis in
which PM5-definitions were nonoverlapping (exclusive)
and compared with a reference baseline band. PM5_band_x
was defined as there being only 1 colocated DEL variant
compared with which the variant under examination had an
equal or more damaging in silico score. PM5_band_y was
defined as there being 2 or more colocated DEL variants
compared with which the variant under examination had an
equal or more damaging in silico score than at least 1colocated variant. The baseline_band comprised all variants
not meeting the criteria for PM5_band_x or PM5_band_y
(Table 2, Supplemental Tables 7 and 8).
To examine the effect of occult midexonic spliceogenic
base substitutions (excluding the para-splice-site variants),
we used quantitative RNA sequencing data available for the
BRCA1 variants.16 We conducted the full PM5 analyses
including and then excluding these 31 midexonic variants for
which theRNA levelwas intermediate (17 variants [14DEL/3
TOL]) or depleted (14 variants [all DEL]) (Supplemental
Table 9).Results
Excluding ineligible variants and codons, across the 311
codons spanning the RING domain (amino acids 1-98) and
Table 1 Positive LR for different definitions of PM5 for binary analyses of data for (1) BRCA1 and MSH2 combined, (2) BRCA1, and (3) MSH2
PM5-Definition Tool
BRCA1 + MSH2 BRCA1 MSH2
TP FN FP TN Positive LR TP FN FP TN Positive LR TP FN FP TN Positive LR
PM5_a ≥ 1 deleterious reference
variants at codon
245 556 244 6496 8.4 (7.2-9.9) 161 233 97 1316 5.9 (4.7-7.4) 84 323 147 5180 7.5 (5.8-9.6)
PM5_b ≥ 2 deleterious reference
variants at codon
111 690 59 6681 15.8 (11.6-21.4) 84 310 29 1384 10.3 (6.8-15.4) 27 380 30 5297 11.8 (7.1-19.5)
PM5_c ≥ 1 deleterious reference
variant at codon; variant under
examination has an equal or more
damaging in silico score than ≥1
colocated variant
REVEL 122 679 52 6688 19.6 (14.3-26.9) 84 310 15 1398 19.5 (11.5-33.2) 38 369 37 5290 13.4 (8.6-20.8)
Meta-SNP 145 656 29 6711 41.5 (28.1-61.2) 99 295 9 1404 37.5 (19.5-72.3) 46 361 20 5307 29.6 (17.8-49.3)
CADD 154 647 77 6663 16.8 (12.9-21.8) 109 285 37 1376 10.5 (7.3-14.9) 45 362 40 5287 14.7 (9.7-22.1)
Grantham Score 142 659 50 6690 23.7 (17.4-32.4) 90 304 20 1393 15.8 (9.9-25.2) 52 355 30 5297 22.5 (14.6-34.7)
aGVGD 141 660 54 6686 21.8 (16.1-29.6) 90 304 14 1399 22.3 (13.0-38.5) 51 356 40 5287 16.6 (11.1-24.8)
BLOSUM45 133 668 40 6700 27.7 (19.6-39.1) 91 303 12 1401 26.2 (14.7-46.8) 42 365 28 5299 19.5 (12.2-31.0)
BLOSUM62 139 662 42 6698 27.6 (19.7-38.6) 93 301 12 1401 26.8 (15.0-47.8) 46 361 30 5297 19.9 (12.8-31.1)
BLOSUM80 133 668 43 6697 25.8 (18.5-36.0) 87 307 12 1401 25.1 (14.0-44.8) 46 361 31 5296 19.3 (12.4-30.0)
PM5_d ≥ 2 deleterious reference
variants at codon; variant under
examination has an equal or more
damaging in silico score than ≥1
colocated variant
REVEL 69 732 15 6725 37.7 (21.8-65.0) 53 341 4 1409 42.6 (16.4-110.7) 16 391 11 5316 18.7 (8.9-39.5)
Meta-SNP 81 720 6 6734 105.4 (47.6-233.5) 62 332 4 1409 49.7 (19.2-128.6) 19 388 2 5325 101.9 (27.4-378.6)
CADD 86 715 28 6712 25.5 (16.8-38.7) 68 326 16 1397 14.9 (8.8-25.1) 18 389 12 5315 19.3 (9.5-39.3)
Grantham Score 73 728 5 6735 112.3 (47.4-266.3) 52 342 2 1411 75.2 (21.2-266.0) 21 386 3 5324 80.2 (26.0-247.1)
aGVGD 72 729 19 6721 31.3 (19.1-51.2) 52 342 2 1411 75.2 (21.2-266.0) 20 387 17 5310 15.3 (8.1-28.7)
BLOSUM45 77 724 9 6731 68.6 (35.1-134.0) 58 336 4 1409 46.5 (18.0-120.6) 19 388 5 5322 46.3 (18.1-118.6)
BLOSUM62 83 718 10 6730 66.8 (35.3-126.5) 61 333 4 1409 48.9 (18.9-126.6) 22 385 6 5321 45.2 (19.0-107.6)
BLOSUM80 79 722 9 6731 70.3 (36.0-137.3) 59 335 3 1410 60.9 (20.8-177.8) 20 387 6 5321 41.2 (17.1-98.9)
PM5_e ≥ 2 deleterious reference
variants at codon; variant under
examination has an equal or more
damaging in silico score than ≥ 2
colocated variants
REVEL 42 759 7 6733 47.6 (22.0-103.2) 34 360 1 1412 82.3 (16.1-420.6) 8 399 6 5321 17.1 (6.2-47.2)
Meta-SNP 49 752 3 6737 118.9 (40.3-350.6) 36 358 2 1411 52.3 (14.6-187.3) 13 394 1 5326 117.5 (21.8-633.1)
CADD 52 749 17 6723 25.2 (14.8-43.1) 43 351 11 1402 13.5 (7.1-25.7) 9 398 6 5321 19.1 (7.1-51.5)
Grantham Score 44 757 1 6739 249.4 (49.1-1,266.8) 34 360 0 1413 247.0 (15.2-4,019.8) 10 397 1 5326 91.4 (16.6-504.3)
aGVGD 43 758 3 6737 104.5 (35.2-309.6) 34 360 0 1413 247.0 (15.2-4,019.8) 9 398 3 5324 35.4 (10.5-120.2)
BLOSUM45 49 752 4 6736 92.5 (35.3-242.0) 41 353 0 1413 297.1 (18.3-4,819.2) 8 399 4 5323 24.7 (7.9-77.0)
BLOSUM62 43 758 5 6735 66.5 (27.5-160.9) 37 357 0 1413 268.5 (16.5-4,362.4) 6 401 5 5322 15.4 (5.0-47.8)
BLOSUM80 46 755 6 6734 60.1 (26.6-136.2) 39 355 1 1412 94.3 (18.5-479.5) 7 400 5 5322 17.8 (6.0-53.3)
Positive likelihood ratios and 95% confidence intervals are shown in bold.






6 L. Loong et al.BRCT domain (amino acids 1631-1855) of BRCA1,
dichotomized functional classifications were available for
1807 missense variants (1413 assay-TOL/394 assay-DEL)
(Figure 2A), distributed as 17 DEL-only codons, 128 mixed
codons, and 166 TOL-only codons (Figure 3A). Dichoto-
mized ClinVar clinical classifications were available for 111
variants (22 B/LB and 89 P/LP).
For MSH2, across the 918 codons studied, dichotomized
functional classifications were available on 5734 missense
variants (5327 assay-TOL/407 assay-DEL) (Figure 2B),
distributed as 6 DEL-only codons, 215 mixed codons, and
697 TOL-only codons (Figure 3B). Dichotomized ClinVar
classifications were available for 88 variants (28 B/LB and
60 P/LP).
In total, 7541 variants were analyzed for each of the 5 PM5
definitions (a-e). Overall, PM5 pLRs were higher when the
PM5-definition was of higher stringency, eg, e > d > b.
Values were broadly similar for BRCA1 andMSH2 (Table 1).
Combining data from the 2 genes, the PM5 pLRwas 8.4 (7.2-
9.9) for PM5-definition_a (variants for which there are 1 or
more colocated DEL variants at the codon) and 15.8 (11.6-
21.4) for PM5-definition_b (variants for which there are 2 or
more colocated DEL variants at the codon).
These PM5 pLR increased with application of the stip-
ulation that the variant under examination should be pre-
dicted to be more damaging than 1 or more of the reference
variants (PM5-definitions c-e) for all 8 tools examined. For
example, the PM5 pLR increased to 27.6 (19.7-38.6) for
PM5-definition_c (where there was 1 or more colocated
DEL variants at the codon and the variant under examina-
tion was equally or more damaging using BLOSUM62 than
at least 1 colocated DEL variant) and to 66.5 (27.5-160.9)
for PM5-definition_e (2 or more colocated DEL variants at
the codon and the variant under examination is more or
equally damaging using BLOSUM62 than 2 or more of
colocated DEL variants).
In the banded analyses of nonoverlapping PM5 defini-
tions compared with a common baseline group, PM5 pLRs
were 16.3 (10.6-24.9) for variants attaining standard x
(exactly 1 colocated DEL variant; variant under examination
equally or more damaging using BLOSUM62) and 71.5
(37.8-135.3) for variants attaining standard y (2 or more
colocated DEL variants; variant under examination equally
or more damaging using BLOSUM62 than at least 1 colo-
cated DEL variant) (Table 2).
The PM5 pLRs were moderately lower when we used
MAVE data both for the PM5-lookup and for the reference
truthset (Supplemental Tables 4 and 7). When using ClinVar
data for the reference truthset and the PM5-lookup (n= 199),
because of smaller numbers, the PM5 pLRs exhibited less
stable patterns and had wider confidence intervals; at higher
stringencies of PM5-definition both the TP rate and FP rate
were very low using the ClinVar data (Supplemental Tables 5
and 8).
Exclusion, in addition to para-splice-site variants, of the
31 potentially spliceogenic exonic variants from the BRCA1analysis had negligible effect on the PM5 pLRs
(Supplemental Table 9).Discussion
In these analyses we sought to quantify how often the
realworld approach of PM5 is correct. We generated PM5
predictions by lookup in ClinVar of clinically classified
colocated DEL (pathogenic) variants. However, we refer-
enced these predictions against a comprehensive, unbiased
truthset of functional classifications available for (nearly)
every putative variant under examination. We conducted our
analyses using BRCA1 and MSH2, which are well-
established cancer susceptibility genes for which there
have been high volumes of clinical testing and long-
established expert groups for clinical variant interpreta-
tion.25,26 Although the number of BRCA1/MSH2 missense
variants for which dichotomized classifications are available
in ClinVar is still small compared with the total number of
potential missense variants, this number is far greater than
for most other genes. For other genes there typically will be
fewer clinical classifications of DEL (pathogenic) variants
available to generate TP PM5-calls, meaning that for a
greater proportion of genuinely DEL (pathogenic) variants
under examination, PM5 will not be attainable. Accord-
ingly, for genes with more sparse clinical classifications, the
PM5 pLR estimates presented here are likely to be
conservative.
For MSH2 the described functional domains were
distributed across the length of the gene, and no clustering
of DEL variants was evident in the MAVE data. By
contrast, for BRCA1, MAVE data were only available for
the RING and BRCT domains owing to established doctrine
that there are no DEL (pathogenic) missense variants
located outside of these domains. The likelihood ratios were
higher for MSH2 than for BRCA1 for basic definitions of
PM5 (definitions a and b), although there was some vari-
ability when in silico predictions were incorporated into the
definitions. For MSH2, in total, 407 of 5734 (7.1%)
missense variants were MAVE-DEL, whereas 697 of 918
(75.9%) codons harbored only MAVE-TOL variants
(Figure 3B). By contrast, for BRCA1, 394 of 1807 (21.8%)
missense variants were MAVE-DEL, whereas 166 of 311
(53.4%) codons harbored only MAVE-TOL variants
(Figure 3A). There are 1533 intervening BRCA1 codons not
covered by the Findlay et al16 MAVE. If, as presumed, those
codons are less important to protein structure and function,
single-nucleotide variation at those codons would be largely
MAVE TOL. This would increase the TN rate, and thus, the
prediction would be that inclusion of a full BRCA1 variant
set would result in increased PM5 pLRs.
It might be anticipated that variants for which ClinVar
clinical classifications are available would be a nonrandom
sample of all DEL variants, potentially biased toward vari-
ants for which richer clinical data may be available and
Figure 2 Distribution of assay results by codon. By codon, number of multiplex assay of variant effect (MAVE)-deleterious missense
variants (red), number of MAVE-tolerated missense variants (blue), and number of eligible missense (green) for (A) BRCA1 and (B) MSH2.
Figure 3 Distribution of codon types in BRCA1 and MSH2. Number of codons which are MAVE-deleterious only (red), MAVE-
tolerated only (green), and MAVE-mixed (blue) against the total number of missense variants at the codon for which there is dichoto-
mous assay data (x-axis) for (A) BRCA1 and (B) MSH2.
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Table 2 Positive LRs for nonoverlapping bands for PM5 for (1) BRCA1 and MSH2 combined, (2) BRCA1, and (3) MSH2
PM5-Definition-Band Tool
BRCA1 + MSH2 BRCA1 MSH2
TP FN FP TN Positive LR TP FN FP TN Positive LR TP FN FP TN Positive LR
PM5_baseline_band: variants not attaining
criteria for PM5_band_x or PM5_band_y
PM5_band_x) Exactly 1 deleterious colocated
variant at codon; variant under examination
has an equal or more damaging in silico score
than colocated variant; comparison with
baseline variant set
Revel 53 679 37 6688 13.1 (8.7-19.7) 31 310 11 1398 11.3 (5.8-22.0) 22 369 26 5290 11.5 (6.6-20.0)
Meta-SNP 64 656 23 6711 25.6 (16.1-40.9) 37 295 5 1404 28.9 (11.9-70.1) 27 361 18 5307 20.4 (11.4-36.4)
CADD 68 647 49 6663 13.0 (9.1-18.5) 41 285 21 1376 8.3 (5.0-13.7) 27 362 28 5287 13.2 (7.9-22.0)
Grantham Score 69 659 45 6690 14.1 (9.8-20.3) 38 304 18 1393 8.6 (5.0-14.7) 31 355 27 5297 15.8 (9.6-26.0)
aGVGD 69 660 35 6686 18.0 (12.1-26.8) 38 304 12 1399 12.7 (6.8-23.7) 31 356 23 5287 18.3 (10.9-31.0)
BLOSUM45 56 668 31 6700 16.7 (10.8-25.6) 33 303 8 1401 16.5 (7.8-34.7) 23 365 23 5299 13.7 (7.8-24.0)
BLOSUM62 56 662 32 6698 16.3 (10.6-24.9) 32 301 8 1401 16.1 (7.7-34.0) 24 361 24 5297 13.8 (8.0-23.9)
BLOSUM80 54 668 34 6697 14.7 (9.7-22.4) 28 307 9 1401 12.6 (6.1-26.0) 26 361 25 5296 14.3 (8.4-24.3)
PM5_band_y) ≥2 deleterious colocated
variants at codon; variant under examination
has an equal or more damaging in silico score
than ≥1 colocated variant; comparison with
baseline variant set
Revel 69 679 15 6688 40.1 (23.3-69.2) 53 310 4 1398 45.8 (17.6-119.1) 16 369 11 5290 19.7 (9.3-41.5)
Meta-SNP 81 656 6 6711 114.1 (51.5-252.8) 62 295 4 1404 54.7 (21.1-141.3) 19 361 2 5307 108.7 (29.3-403.9)
CADD 86 647 28 6663 27.7 (18.2-42.0) 68 285 16 1376 16.3 (9.7-27.6) 18 362 12 5287 20.6 (10.1-41.9)
Grantham Score 86 647 28 6663 27.7 (18.2-42.0) 52 304 2 1393 82.1 (23.2-290.5) 21 355 3 5297 86.4 (28.0-266.0)
aGVGD 72 660 19 6686 34.0 (20.8-55.8) 52 304 2 1399 82.5 (23.3-291.7) 20 356 17 5287 16.5 (8.8-30.9)
BLOSUM45 77 668 9 6700 73.4 (37.6-143.3) 58 303 4 1401 50.5 (19.5-130.8) 19 365 5 5299 48.9 (19.1-125.1)
BLOSUM62 83 662 10 6698 71.5 (37.8-135.3) 61 301 4 1401 52.9 (20.5-136.9) 22 361 6 5297 47.8 (20.1-113.7)
BLOSUM80 79 668 9 6697 75.0 (38.5-146.4) 59 307 3 1401 65.1 (22.3-190.1) 20 361 6 5296 43.8 (18.2-105.1)
Positive likelihood ratios and 95% confidence intervals are shown in bold.






L. Loong et al. 9toward recognized hot spots. Of BRCA1 P/LP variants in
ClinVar, 62 of 89 (70%) had a colocated P/LP variant in
ClinVar at that codon. For BRCA1 MAVE-DEL variants,
342 of 394 (87%) had a colocated MAVE-DEL variant at
that codon. For MSH2, the proportions were 29 of 60 (48%)
for ClinVar and 286 of 407 (70%) for MAVE data. Thus,
there were more codons appearing to have a singleton DEL
variant in ClinVar than on MAVE data.
In silico tools were incorporated into PM5-definitions so
that PM5 was not automatically awarded simply because
there were colocated DEL variants at the codon, in instances
when the variant under examination appeared to be benign.
The Grantham Score, Align-GVGD, BLOSUM45, BLO-
SUM62, and BLOSUM80 reflect the physiochemical dif-
ference between wild-type and mutant amino acids.
REVEL, Meta-SNP, and CADD are widely-used/high-
performing tools, which integrate a wider range of inputs.
Overall, all the tools refined the predictive value of PM5, but
particular boosting of PM5 pLRs was observed when Meta-
SNP, BLOSUM, or The Grantham Score were incorporated
into PM5. This is on account of these tools generating lower
rates of FP calls. Notably, in this context the tool is used to
compare relative deleteriousness between colocated vari-
ants, rather than being used with a prespecified binary
threshold of pathogenicity, which is more typical in other
tool evaluations.22,27
The FP rate is generally low for all PM5-definitions:
3.2% (244/7541) for the most lenient definition of PM5
(PM5-definition_a) and <1% for more stringent PM5-
definitions. The low FP rate drives high specificity, posi-
tive predictive value, and pLRs for calling of pathogenicity.
However, FN rates are high, particularly with increased
PM5-definition stringency. Thus, the negative predictive
value of PM5 is overall weak and negative likelihood ratios
are largely uninformative. Hence, the PM5 metric is only of
utility for providing evidence toward pathogenicity and not
toward benignity.
Application of PM5 is complicated by pathogenicity due
to spliceogenic mechanisms. For the BRCA1 genomic
DNA–based MAVE, spliceogenic DEL variants should give a
DEL readout. Interestingly, inclusion of a small number of
midexonic potentially spliceogenic variants in BRCA1 had
little effect on PM5 pLRs (Supplemental Table 9). Conversely,
for the MSH2 complementary DNA–based MAVE, spliceo-
genic DEL variants should not give a DEL readout. A pro-
portion of the ClinVar classifications of P/LP were due to
spliceogenic DEL MSH2 variants; these variants would have
inflated the FP rate and dampened the true PM5 pLR for the
DEL variants acting via protein effect.
Limitations
The inherent limitation of these analyses is the use of
MAVE-functional classifications as a truthset for patho-
genicity. However, although clinical classifications aredeemed to be the gold-standard, these are only as good as
the comprehensiveness and accuracy of underlying clin-
ical information and the validity of the classification
schema employed. Dichotomous classifications are only
available in ClinVar for a very modest number of variants;
a particular limitation is the very small number of variants
for which there is a classification of B/LB. Undeniably,
for the BRCA1/MSH2 variants discrepant between Clin-
Var and MAVE-functional classification, whereas spli-
ceogenic mechanism of pathogenicity accounted for some
of the discrepancies, in several cases, the clinical classi-
fication appeared potentially questionable (Supplemental
Table 2).28,29 Intermediate penetrance (hypomorphic ef-
fect) may also contribute to discrepancies between clinical
and functional data.
Although MAVE-functional classifications are unlikely
to perfectly recapitulate true human pathogenesis, given
their powerful correlation against clinical classifications, the
size of the data sets and their systematic generation, argu-
ably represent the best truthsets currently available for this
type of large unbiased evaluation of variant classification
metrics.
Inherent in PM5 is a presumption of universality across
genes that DEL variants will cluster at specific codons that
encode functionally important amino acids. However, the
extent of gene-by-gene variation in the proportion and
tightness of clustering of DEL variants is unclear. Our
estimates for BRCA1 and MSH2 were overall similar but
inclusion of a broader set of genes/MAVEs would be
desirable for further exploration of consistency of PM5
pLRs. Although multiple MAVEs were identified for
other cancer susceptibility genes TP53 and PTEN, they
were not included because of inconsistent correlation
between MAVE-functional data sets and the clinical
classifications.
Clinical application
Overall, we would propose on the basis of these analyses
that graded evidence levels could be applied for PM5 on the
basis of the stringency of PM5 observed. Although incor-
poration of any of the 8 in silico tools examined improved
the magnitude of PM5 discrimination, BLOSUM matrices
and The Grantham Score most simply reflect physi-
ochemical protein difference and provide particularly strong
discrimination. Using BLOSUM62, PM5 pLR for patho-
genicity was found to be 16.3 (10.6-24.9) for a variant under
examination for which there is exactly 1 colocated DEL
variant and the variant under examination is equally or more
damaging (PM5_band_x), and it was found to be 71.5 (37.8-
135.3) for a variant under examination for which there are 2
or more colocated DEL variants and the variant under ex-
amination is equally or more damaging than at least 1
colocated DEL variant (PM5_band_y). Using the Bayesian
formulation of the ACMG/AMP framework proposed by
10 L. Loong et al.Tavtigian et al,10,30 these likelihood ratios would correspond
to exponent points of >3 (moderate) and >5 (strong). Even
the lower CI would still equate comfortably to >3 points
(moderate) and >4 points (strong).10,30,31 Of note, using
BLOSUM62, in total, only 181 of 7541 variants attained
PM5: 88 at the lower level (PM5_band_x) and 93 at the
higher level (PM5_band_y).
However, careful consideration is required in
combining PM5 with evidence items PM1 (hot spot), PS3
(functional data), and PP3 (in silico) to avoid over-
counting of nonorthogonal information.32 First, we would
propose that PM1 should not be used where PM5 is
applied; both of these reflect enrichment for pathogenic
variants within a prescribed region. Second, we would
advocate use of different in silico tools for PM5 and PP3;
measures of protein distance such as BLOSUM and The
Grantham Score are most apposite for PM5 evaluation,
whereas best performance for PP3 is attained by meta
tools such as REVEL and Meta-SNP optimized on mul-
tiple datasources.22 Third, once high quality MAVE data
become available for (nearly) all variants in a gene (or
region), we would deem that PM5 has been superseded
and has become redundant.Data Availability
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